No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial.
Ixico said on Tuesday that the contract value, which will be delivered over approximately two and a half years, was worth more than £500,000 to the company.
The AIM-listed firm added that the contract award reinforced its "sustained positive commercial momentum" and aligns with its strategic pillars to drive expansion and growth.
Chief executie Bram Goorden said: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease.
"This contract further demonstrates Ixico's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors."
As of 1045 GMT, Ixico shares were up 0.093% at 10.76p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
